Veracyte, Inc. (VCYT)

NGM – Цена в реальном времени. Валюта: USD

60.49

+1.94 (3.31%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

60.37

-0.12 (-0.20%)

После закрытия: Jun 26, 2026, 7:58 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Veracyte, Inc. (VCYT)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Veracyte, Inc. (VCYT)

Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term

Here's Why Veracyte (VCYT) is a Strong Growth Stock

Why Is Veracyte (VCYT) Up 18.2% Since Last Earnings Report?

Veracyte, Inc. (VCYT) Discusses ASCO Findings From OPTIMA and ENZAMET Phase III Trials in Breast and Prostate Cancer Transcript

Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.

ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer

Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte's Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy

Видео

No Data

Пресс-релизы

Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.

ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer

Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte's Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy

Veracyte to Host Investor Call on June 1, 2026 to Discuss ASCO Findings

Search stocks

Veracyte, Inc. (VCYT)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Veracyte, Inc. (VCYT)

Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term

Here's Why Veracyte (VCYT) is a Strong Growth Stock

Why Is Veracyte (VCYT) Up 18.2% Since Last Earnings Report?

Veracyte, Inc. (VCYT) Discusses ASCO Findings From OPTIMA and ENZAMET Phase III Trials in Breast and Prostate Cancer Transcript

Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.

ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer

Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte's Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy

Видео

No Data

Пресс-релизы

Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.

ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer

Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte's Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy

Veracyte to Host Investor Call on June 1, 2026 to Discuss ASCO Findings